FDA Sends Letters to Quest, LabCorp About Ovarian Cancer Test | GenomeWeb

Throwing yet another wrench into plans to release a mass spec pattern-based ovarian cancer test for home brew use, the FDA sent twin letters last week to Quest Diagnostics and Laboratory Corporation of America. The letters warned that the test these two companies licensed from Correlogic Systems for possible home brew use may be subject to premarket review.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.